GBA1

Chr 1ADMultiAR

glucosylceramidase beta 1

Also known as: GBA, GCB, GLUC

This gene encodes a lysosomal membrane protein that cleaves the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism. Mutations in this gene cause Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. A related pseudogene is approximately 12 kb downstream of this gene on chromosome 1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2010]

Primary Disease Associations & Inheritance

{Lewy body dementia, susceptibility to}MIM #127750
AD
{Parkinson disease, late-onset, susceptibility to}MIM #168600
ADMulti
Gaucher disease, perinatal lethalMIM #608013
AR
Gaucher disease, type IMIM #230800
AR
Gaucher disease, type IIMIM #230900
AR
Gaucher disease, type IIIMIM #231000
AR
Gaucher disease, type IIICMIM #231005
AR
UniProtGaucher disease 1
UniProtGaucher disease 2
UniProtGaucher disease 3
UniProtGaucher disease 3C
582
ClinVar variants
208
Pathogenic / LP
0.00
pLI score
12
Active trials
Clinical SummaryGBA1
🧬
Gene-Disease Validity (ClinGen)
Parkinson disease · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

2 total gene-disease associations curated

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
208 Pathogenic / Likely Pathogenic· 269 VUS of 582 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.80LOEUF
pLI 0.000
Z-score 2.36
OE 0.51 (0.340.80)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
1.17Z-score
OE missense 0.81 (0.730.90)
248 obs / 305.8 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.51 (0.340.80)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.81 (0.730.90)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.05
01.21.6
LoF obs/exp: 14 / 27.3Missense obs/exp: 248 / 305.8Syn Z: -0.40

ClinVar Variant Classifications

582 submitted variants in ClinVar

Classification Summary

Pathogenic89
Likely Pathogenic119
VUS269
Likely Benign51
Benign7
Conflicting47
89
Pathogenic
119
Likely Pathogenic
269
VUS
51
Likely Benign
7
Benign
47
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
18
41
30
0
89
Likely Pathogenic
23
78
18
0
119
VUS
3
201
37
28
269
Likely Benign
0
2
8
41
51
Benign
0
1
6
0
7
Conflicting
47
Total443239969582

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

GBA1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

GBA1-related Gaucher disease perinatal lethal

definitive
ARLoss Of FunctionAbsent Gene Product
Dev. DisordersSkin
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

{Lewy body dementia, susceptibility to}

MIM #127750

Molecular basis of disorder known

Autosomal dominant

{Parkinson disease, late-onset, susceptibility to}

MIM #168600

Molecular basis of disorder known

Autosomal dominantMultifactorial

Gaucher disease, perinatal lethal

MIM #608013

Molecular basis of disorder known

Autosomal recessive

Gaucher disease, type I

MIM #230800

Molecular basis of disorder known

Autosomal recessive

Gaucher disease, type II

MIM #230900

Molecular basis of disorder known

Autosomal recessive

Gaucher disease, type III

MIM #231000

Molecular basis of disorder known

Autosomal recessive

Gaucher disease, type IIIC

MIM #231005

Molecular basis of disorder known

Autosomal recessive
📖
GeneReview available — GBA1
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Parkinson Disease

Effectiveness of Cognitive Stimulation Treatment in Patients With Parkinson's Disease

RECRUITING
NCT06323278Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoStarted 2021-12-21
Cognitive training
Parkinson DiseaseGBA Gene MutationGaucher Disease

The GBA Multimodal Study in Parkinson's Disease

RECRUITING
NCT04101968Pacific Parkinson's Research CentreStarted 2019-05-01
PET scanneuroQWERTY
Parkinson Disease

Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease

ENROLLING BY INVITATION
NCT06451419Juan Pablo Romero. MD, PhDStarted 2024-07-01
Tests on non motor symptoms
Parkinson's Disease

Genotypic Influences on Network Progression in Parkinson's Disease

ACTIVE NOT RECRUITING
NCT04228172Northwell HealthStarted 2020-02-24
DNA/GeneticTestingFDG PET scanMRI scan
Parkinson Disease

Chinese PD-GBA Registry

RECRUITING
NCT03523065Xiangya Hospital of Central South UniversityStarted 2017-02-01
Gaucher Disease, Type 2

Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

ACTIVE NOT RECRUITING
NCT04411654Phase PHASE1, PHASE2Prevail TherapeuticsStarted 2021-06-29
LY3884961MethylprednisoloneSirolimus
Parkinson Disease

PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's

RECRUITING
NCT06151002University College London HospitalsStarted 2020-02-15
Monoclonal Gammopathy of Undetermined SignificanceMyeloma Multiple

Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

NOT YET RECRUITING
NCT06559033University Hospital, RouenStarted 2025-06-01
Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS
Gaucher Disease

Screening for Gaucher Disease and Acid Sphingomyelinase Deficiency

NOT YET RECRUITING
NCT06258577Chung-Hsing WangStarted 2024-05-01
Parkinson DiseaseGaucher DiseaseHealthy

Drug Discovery for Parkinson's With Mutations in the GBA Gene

RECRUITING
NCT05536388New York Stem Cell Foundation Research InstituteStarted 2022-07-15
Biological Sample Collection
Parkinson's Disease

Prevent Cognitive Decline in GBA-associated Parkinson's Disease

NOT YET RECRUITING
NCT07055087Phase PHASE2University Hospital TuebingenStarted 2025-12
PrasinezumabSodium Chloride
Idiopathic Parkinson&#39;s Disease (PD)

Study on the Incidence of Malignant Neoplasms in Patients with Parkinson's Disease and Heterozygous Mutation of the GBA Gene

RECRUITING
NCT06814431Azienda USL Reggio Emilia - IRCCSStarted 2023-11-23